TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7010528

Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium (Biogastrone tablets) 100 mg three times a day for 4 weeks, continued for another 4 weeks if ulcers were not healed
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dummy tablets (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amiloride 5 mg three times a day
Number of subjects: 40
Study: 31834128

Group type: EXPERIMENTAL
Intervention: Unattended automated office blood pressure (AOBP)
Number of subjects: 2588

Group type: COMPARATOR
Intervention: Auscultatory BP
Number of subjects: 2588

Group type: COMPARATOR
Intervention: Attended oscillometric AOBP
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Unattended AOBP
Number of subjects: 2588
Study: 31151334

Group type: EXPERIMENTAL
Intervention: Blunt needle
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sharp needle
Number of subjects: 108
Study: 28007444

Group type: EXPERIMENTAL
Intervention: Single‐session educational intervention with written materials provided in English or Spanish
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wait‐list control group
Number of subjects: 52
Study: 25779222

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - three sessions in 3 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 29
Study: 25098969

Group type: EXPERIMENTAL
Intervention: Discontinued medications
Number of subjects: 450
Study: 22839577

Group type: EXPERIMENTAL
Intervention: Sustained low efficiency dialysis using a single-pass batch dialysis system (SLED-BD)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: SLED-BD
Number of subjects: 232

Group type: COMPARATOR
Intervention: CVVH
Number of subjects: 232
Study: 19749003

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF-DPI) 400 microg (1 x 400 microg/inhalation; treatment B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF-DPI) 400 microg (2 x 200 microg/inhalation; treatment A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (two inhalations; treatment C)
Number of subjects: 0
Study: 17652247

Group type: EXPERIMENTAL
Intervention: 5A's intervention
Number of subjects: 2177

Group type: EXPERIMENTAL
Intervention: 3A's intervention
Number of subjects: 2177

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2177
Study: 15784639

Group type: EXPERIMENTAL
Intervention: Pre-dilution on-line haemofiltration (HF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-flux haemodialysis (HD)
Number of subjects: 40
Study: 11888956

Group type: EXPERIMENTAL
Intervention: Home unattended polysomnography (H‐PSG)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Polysomnography performed in a local hospital and telemonitored by a sleep laboratory (T‐PSG)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Patient preference for H‐PSG
Number of subjects: 99

Group type: COMPARATOR
Intervention: Patient preference for T‐PSG
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Comparison of sleep and respiratory indexes
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Concordance of H‐PSG and T‐PSG
Number of subjects: 99
Study: 10210343

Group type: EXPERIMENTAL
Intervention: Thin-section computed tomography (CT)
Number of subjects: 34
Study: 7607973

Group type: EXPERIMENTAL
Intervention: Adjuvant extracorporeal photochemotherapy (ECP)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin/cyclophosphamide
Number of subjects: 163

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Adjuvant therapies (ECP and doxorubicin/cyclophosphamide)
Number of subjects: 163
Study: 3138056

Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prazepham (20 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 30708393

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 24

Group type: COMPARATOR
Intervention: No Milrinone (Control)
Number of subjects: 24
Study: 31377075

Group type: EXPERIMENTAL
Intervention: GC3114 (high-dose, quadrivalent influenza vaccine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (standard-dose quadrivalent influenza vaccine)
Number of subjects: 100
Study: 26994300

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide infusion (1.5 µg/min)
Number of subjects: 40
Study: 26321502

Group type: EXPERIMENTAL
Intervention: Standard-dose epirubicin and cyclophosphamide (SDE) (8 × 60 mg/m(2))
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Higher-dose epirubicin and cyclophosphamide (HDE) (8 × 100 mg/m(2))
Number of subjects: 777

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, fluorouracil (CMF)
Number of subjects: 777
Study: 24217684

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 88

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 88
Study: 21360584

Group type: EXPERIMENTAL
Intervention: EtO‐sterilized non‐cross‐linked Reflection All-Poly cups
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oxinium femoral heads
Number of subjects: 150

Group type: COMPARATOR
Intervention: Charnley Ogee acetabular cup
Number of subjects: 150
Study: 18630561

Group type: EXPERIMENTAL
Intervention: Four-strand semitendinosus tendon autograft
Number of subjects: 42

Group type: COMPARATOR
Intervention: LARS artificial ligament
Number of subjects: 42
Study: 20553629

Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa leaf extract (1 gm/day for 90 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, similar amount for 90 days)
Number of subjects: 60
Study: 16118787

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99
Study: 12117043

Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg bd
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg bd
Number of subjects: 85

Group type: COMPARATOR
Intervention: Theophylline (Theo-Dur 300 mg bd)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 85
Study: 9570170

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg 3 times a day plus Omeprazole 40 mg daily for 14 days followed by 20 mg daily for 14 days (Group 1)
Number of subjects: 819

Group type: COMPARATOR
Intervention: Omeprazole 20 mg daily for 28 days (Group 2)
Number of subjects: 819

Group type: COMPARATOR
Intervention: Ranitidine hydrochloride 150 mg twice a day for 28 days (Group 3)
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Clarithromycin plus Omeprazole (Group 1)
Number of subjects: 819
Study: 7851071

Group type: EXPERIMENTAL
Intervention: OpSite dressings
Number of subjects: 33
Study: 3049046

Group type: EXPERIMENTAL
Intervention: Pirenzepin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 100
Study: 16961011

Group type: EXPERIMENTAL
Intervention: Operant conditioning with positive reinforcements of candy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Interpretive play therapy
Number of subjects: 20
Study: 30246216

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30268262

Group type: EXPERIMENTAL
Intervention: Kefir group (2 × 100 ml of kefir per day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Toothpaste group (toothpaste with probiotic content, brushed twice a day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no probiotic treatment)
Number of subjects: 45
Study: 27046162

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Ticagrelor (pooled doses)
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1143
Study: 24473502

Group type: EXPERIMENTAL
Intervention: Amiodarone plus ranolazine (1500 mg single oral dose)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 121
Study: 21538705

Group type: EXPERIMENTAL
Intervention: Elderly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young controls
Number of subjects: 0
Study: 21070678

Group type: EXPERIMENTAL
Intervention: Low-Glycemic Load (LGL) breakfast
Number of subjects: 23

Group type: COMPARATOR
Intervention: High-Glycemic Load (HGL) breakfast
Number of subjects: 23
Study: 17105777

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15581647

Group type: EXPERIMENTAL
Intervention: Psychological attributions and perception-related factors
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lower age, male sex, CFS-like caseness, and less cognitive difficulties
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lower physical functioning scores
Number of subjects: 151
Study: 11281469

Group type: EXPERIMENTAL
Intervention: Psychosocial factors (unemployment, anxiety, perceived inconvenience, abdominal pain, haemoglobin level, serum ferritin concentration)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Normal menstrual blood loss (<60 mL)
Number of subjects: 226
Study: 9690973

Group type: EXPERIMENTAL
Intervention: Sertindole (12-24 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertindole (24 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8045864

Group type: EXPERIMENTAL
Intervention: Electronic foot contact monitor for estimating metabolic cost of locomotion (Mloco)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Equation derived from six subjects: Mloco = 3.702.(Wb/tc) - 149.6 (r2 = 0.93)
Number of subjects: 12
Study: 3132812

Group type: EXPERIMENTAL
Intervention: Active ankle movements with weight bearing in an orthosis
Number of subjects: 51

Group type: COMPARATOR
Intervention: Active ankle movements without weight bearing using a dorsal splint
Number of subjects: 51
Study: 29576227

Group type: EXPERIMENTAL
Intervention: Intervention group (duration longer than 1 year)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (duration longer than 1 year)
Number of subjects: 216
Study: 26957279

Group type: EXPERIMENTAL
Intervention: Hemoperfusion combined therapy (HD+HP)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional hemodialysis (HD)
Number of subjects: 92
Study: 26434090

Group type: EXPERIMENTAL
Intervention: Anterolateral joint line injection site
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Suprapatellar lateral injection site
Number of subjects: 60
Study: 24145083

Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (Healthy subjects)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (RA patients)
Number of subjects: 78
Study: 21173687

Group type: EXPERIMENTAL
Intervention: Metenolone enanthate (ME) 100 mg injected intramuscularly weekly for 6 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CT)
Number of subjects: 26
Study: 18313521

Group type: EXPERIMENTAL
Intervention: Multicatheter interstitial brachytherapy (n=247) or MammoSite (n=26), receiving 32-34 Gy in 8-10 twice-daily fractions using high-dose-rate 192Ir brachytherapy.
Number of subjects: 273
Study: 16550749

Group type: EXPERIMENTAL
Intervention: PEG-Hirudin (PEG-H)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 20
Study: 12893716

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10579155

Group type: EXPERIMENTAL
Intervention: New paste preparation of Gelfoam powder, Thrombostat, acetic acid, and Bacitracin ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Old method using small pieces of Gelfoam soaked in antibiotic solution
Number of subjects: 0
Study: 8723582

Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation (ABD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perioperative treatment with epoetin alfa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of epoetin alfa and preoperative ABD
Number of subjects: 0
Study: 1896663

Group type: EXPERIMENTAL
Intervention: Computer analysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Point-counting method
Number of subjects: 20
Study: 7037511

Group type: EXPERIMENTAL
Intervention: Highly purified porcine insulin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Highly purified porcine insulin (after removing patients with substantial changes in HbA1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Highly purified porcine insulin (after removing patients with low initial insulin binding capacity)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bovine insulin (after rechallenge)
Number of subjects: 40
Study: 28547866

Group type: EXPERIMENTAL
Intervention: Pneumatic Dilation (PD)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Laparoscopic Heller Myotomy (LHM)
Number of subjects: 201
Study: 26934504

Group type: EXPERIMENTAL
Intervention: 7-days-a-week post-operative radiotherapy (p-CAIR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Post-operative concurrent radiochemotherapy (p-RTCT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both p-CAIR and p-RTCT
Number of subjects: 84
Study: 24687640

Group type: EXPERIMENTAL
Intervention: 16 mg nicotine patch applied during the night
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 21708892

Group type: EXPERIMENTAL
Intervention: Dilute rice vinegar (100 ml daily for 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (100 ml of water)
Number of subjects: 60
Study: 19915220

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 177

Group type: COMPARATOR
Intervention: Right ventricular apical pacing
Number of subjects: 177
Study: 17907858

Group type: EXPERIMENTAL
Intervention: Computerized drawing with high density (CH)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Computerized drawing with standard density (CS)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Manual drawing with standard prize density (MS)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Noncontingent control group (NonC)
Number of subjects: 116
Study: 14967827

Group type: EXPERIMENTAL
Intervention: 250 mg of caffeine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 600 mg of caffeine per day for 5 days
Number of subjects: 97
Study: 12565114

Group type: EXPERIMENTAL
Intervention: Ropivacaine-fentanyl patient-controlled epidural analgesia (PCEA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (IV PCA)
Number of subjects: 41
Study: 10433003

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 67

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 67
Study: 7586105

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg i.v.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Midazolam infusion (0.3-0.5 mg.min-1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg)
Number of subjects: 16
Study: 2239119

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (bolus) followed by 0.25% (infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (bolus) followed by 0.125% (infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% and 0.25%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% and 0.25%
Number of subjects: 20
Study: 6767295

Group type: EXPERIMENTAL
Intervention: Mistabron (sodium‐2‐mercaptoethane sulphonate)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Iso‐osmolar hypertonic saline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mistabron
Number of subjects: 27
Study: 29891745

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (800 IU/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 27702425

Group type: EXPERIMENTAL
Intervention: Nutrition education (NE) combined with agriculture intervention
Number of subjects: 921

Group type: COMPARATOR
Intervention: Agriculture intervention only (Control)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Nutrition education (NE)
Number of subjects: 921
Study: 24637559

Group type: EXPERIMENTAL
Intervention: Low-dose sildenafil
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Medium-dose sildenafil
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: High-dose sildenafil
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 234
Study: 22798533

Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 1386

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: 80% oxygen in cancer surgery
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: 80% oxygen in noncancer surgery
Number of subjects: 1386
Study: 20479228

Group type: EXPERIMENTAL
Intervention: Experimental group with newly trained lexical categories for color (e.g., different shades of blue acquiring new names)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no new categories introduced, conditions matched to the experimental group
Number of subjects: 0
Study: 18191684

Group type: EXPERIMENTAL
Intervention: Daily spontaneous awakening trials (SATs) followed by spontaneous breathing trials (SBTs)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Sedation per usual care plus a daily SBT
Number of subjects: 336
Study: 15625071

Group type: EXPERIMENTAL
Intervention: Gentamicin cream
Number of subjects: 133

Group type: COMPARATOR
Intervention: Mupirocin cream
Number of subjects: 133
Study: 12566639

Group type: EXPERIMENTAL
Intervention: Preventive measures (specific measures not detailed)
Number of subjects: 1165

Group type: EXPERIMENTAL
Intervention: Increment analysis
Number of subjects: 1165

Group type: EXPERIMENTAL
Intervention: Incidence density analysis
Number of subjects: 1165
Study: 10825329

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) at 10 mA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cold, pinprick, and touch sensory block
Number of subjects: 80
Study: 9003134

Group type: EXPERIMENTAL
Intervention: Orthodontist-delivered tobacco-use prevention program
Number of subjects: 15464

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15464
Study: 1544196

Group type: COMPARATOR
Intervention: 50% oxygen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 20
Study: 6379305

Group type: EXPERIMENTAL
Intervention: Intermittent aortic cross‐clamping at 32 degrees C
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intermittent aortic cross‐clamping at 25 degrees C
Number of subjects: 72

Group type: COMPARATOR
Intervention: St. Thomas' Hospital cardioplegia
Number of subjects: 72
Study: 3093773

Group type: EXPERIMENTAL
Intervention: Peripheral intravenous dextrose infusion
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Peripheral intravenous amino acid infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 25
Study: 31712981

Group type: COMPARATOR
Intervention: Conventional‐F toothpaste (1,450 μg F/g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional‐F + arginine/CaCO3 (1,450 μg F/g + 1.5% arginine‐CaCO3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High‐F toothpaste (5,000 μg F/g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High‐F + fTCP toothpaste (5,000 μg F/g)
Number of subjects: 12
Study: 29199116

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 75

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 75
Study: 26892128

Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin (E/S)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Atorvastatin (ATV)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin + Atorvastatin (E/S + ATV)
Number of subjects: 1054
Study: 23276524

Group type: EXPERIMENTAL
Intervention: Combined treatment (pharmacological + psychoeducational and cognitive-behavioral therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard pharmacological treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Experimental group (combined treatment)
Number of subjects: 40
Study: 22776535

Group type: EXPERIMENTAL
Intervention: 6 mJ/MTZ with high MTZ density (up to 2,625 MTZ/cm²)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 70 mJ/MTZ with lower MTZ density (up to 230 MTZ/cm²)
Number of subjects: 11
Study: 19709693

Group type: COMPARATOR
Intervention: Diet (reduced total fat, saturated fat, and cholesterol intake)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Diet + PA
Number of subjects: 274

Group type: COMPARATOR
Intervention: Diet or Diet + PA
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control
Number of subjects: 274
Study: 18313273

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: AUIC > or = 250
Number of subjects: 107

Group type: COMPARATOR
Intervention: AUIC < 250
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: T > MIC of 100%
Number of subjects: 107

Group type: COMPARATOR
Intervention: T > MIC of <100%
Number of subjects: 107
Study: 15967639

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12663559

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1274
Study: 10636205

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors
Number of subjects: 3154
Study: 8831325

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 0.3 microgram/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 6%
Number of subjects: 30